CatalystWireBeta

Capital Markets Day

In brief · summary, not quotable

No summary for this filing – the full text is below.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your EAH notes

Capital

ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that it is hosting a Capital Markets Day (“CMD”) today for institutional investors and analysts from 09:30 GMT in the City of London.

Presentations will be given by David Hallas, Chief Executive Officer; Chris Wilks, Chief Financial Officer; Andrew Buglass, Chief Commercial Officer and other members of ECO’s senior leadership team. Topics that will be covered include:

Commercial strategy and execution for Aivlosin® and ECOVAXXIN® MS;

Business development priorities and growth opportunities;

Updates on ECO’s R&D pipeline, including the Company’s current valuation framework for its portfolio. This includes a risk adjusted sum of the parts enterprise valuation for ECOVAXXIN® MS and the R&D portfolio of c. £100m. In addition, PRRSvmAb which is at proof-of-concept stage, is described and provides an indicative valuation range of £0 - £100m dependent on a key trial completing in the near term.

The event will also include recorded interviews from external speakers including Eurovo, a leading European egg producer which will share its experience with ECOVAXXIN® MS, and Pr. Didier Betbeder, Chief Executive Officer of Vaxinano. In August 2026, ECO signed an exclusive in-licensing agreement with Vaxinano for a sheep vaccine candidate against toxoplasmosis.

David Hallas, Chief Executive Officer of ECO Animal Health, shared: “We look forward to connecting with investors and analysts to demonstrate ECO’s positive progress to date and highlight how we are driving the next generation of animal health products.

With a resilient core business, a self-funded R&D pipeline that has already yielded a commercialised vaccine and a clear business development strategy, ECO is well placed for our next phase of growth.”

The CMD presentation will be available at ecoanimalhealth.com/investors/reports-presentations following the event. Save as above, no new material disclosures will be made at the event.

Cleaned text: letterheads, contacts and legal notices removed. Official copy: FCA National Storage Mechanism ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note